User profiles for "author:A Stewart"

A. keith stewart

- Verified email at uhn.ca - Cited by 45926

Alexandre FR Stewart

- Verified email at ottawaheart.ca - Cited by 39616

Alistair W Stewart

- Verified email at auckland.ac.nz - Cited by 37434

A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress

D Del Rio, AJ Stewart, N Pellegrini - Nutrition, metabolism and …, 2005 - Elsevier
AIM: Of the many biological targets of oxidative stress, lipids are the most involved class of
biomolecules. Lipid oxidation gives rise to a number of secondary products …

STrengthening the REporting of Genetic Association Studies (STREGA)—an extension of the STROBE statement

…, R King, C Infante‐Rivard, A Stewart… - … Official Publication of …, 2009 - Wiley Online Library
Making sense of rapidly evolving evidence on genetic associations is crucial to making
genuine advances in human genomics and the eventual integration of this information in the …

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review

R Fonseca, PL Bergsagel, J Drach, J Shaughnessy… - Leukemia, 2009 - nature.com
Myeloma is a malignant proliferation of monoclonal plasma cells. Although morphologically
similar, several subtypes of the disease have been identified at the genetic and molecular …

[HTML][HTML] Intratumor heterogeneity and branched evolution revealed by multiregion sequencing

…, P Martinez, N Matthews, A Stewart… - New England journal …, 2012 - Mass Medical Soc
Background Intratumor heterogeneity may foster tumor evolution and adaptation and hinder
personalized-medicine strategies that depend on results from single tumor-biopsy samples …

The genome sequence of Schizosaccharomyces pombe

…, MA Rajandream, M Lyne, R Lyne, A Stewart… - Nature, 2002 - nature.com
We have sequenced and annotated the genome of fission yeast (Schizosaccharomyces
pombe), which contains the smallest number of protein-coding genes yet recorded for a …

An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19

DR Owen, CMN Allerton, AS Anderson… - Science, 2021 - science.org
The worldwide outbreak of COVID-19 caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) has become a global pandemic. Alongside vaccines, antiviral …

[HTML][HTML] Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV …

…, R Lyon, C McDonnell, C Cole, A Stewart… - The Lancet, 2021 - thelancet.com
Background Few data exist on the comparative safety and immunogenicity of different
COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection …

Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line

SPC Cole, G Bhardwaj, JH Gerlach, JE Mackie… - Science, 1992 - science.org
The doxorubicin-selected lung cancer cell line H69AR is resistant to many
chemotherapeutic agents. However, like most tumor samples from individuals with this …

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma …

JG Berdeja, D Madduri, SZ Usmani, A Jakubowiak… - The Lancet, 2021 - thelancet.com
Background CARTITUDE-1 aimed to assess the safety and clinical activity of ciltacabtagene
autoleucel (cilta-cel), a chimeric antigen receptor T-cell therapy with two B-cell maturation …

[HTML][HTML] Tracking the evolution of non–small-cell lung cancer

…, Z Szallasi, RF Schwarz, A Stewart… - … England Journal of …, 2017 - Mass Medical Soc
Background Among patients with non–small-cell lung cancer (NSCLC), data on intratumor
heterogeneity and cancer genome evolution have been limited to small retrospective …